Syneos taking Enteris’s endometriosis treatment to Ph IIa

By Melissa Fassbender contact

- Last updated on GMT

(Image: Getty/shutter_m)
(Image: Getty/shutter_m)
Enteris BioPharma has completed recruitment and initial dosing of all subjects for an additional treatment arm of its Phase IIa clinical trial, which is being conducted by Syneos.

Enteris BioPharma, Inc. is a biotechnology company developing drug products built around its proprietary delivery technologies.

The Phase IIa clinical trial of Ovarest is being conducted in Canada by the contract research organization (CRO) Syneos, which also conducted the Phase I study, Brian Zietsman, president and CFO of Enteris BioPharma told us.

Ovarest is being developed for the treatment of endometriosis and uses Enteris’ formulation technology Peptelligence, which enables oral delivery of molecules that are typically injected.

“A successful completion of the Phase IIa will be our proof of concept study,”​ added Zietsman.

“We expect to be in a position to announce results from the Phase IIa study in early Q3 this year, and will put us on track to initiate our Phase IIb study in the second half of this year.”

Related topics: Clinical Development

Related news

Show more

Follow us

Featured Events

View more

Products

View more

Webinars